German developer of next-generation CAR-T cell therapies for cancer patients, T-CURX GmbH, has announced the appointments of Dr Hans-Peter (HP) Gerber as chairman.
Additionally, Dr Bernd Eschgfäller has been named as an independent board member. Both appointments are effective immediately.
Dr Gerber has a strong industry background with prior leadership and senior management positions at industry leading organizations including Genentech, Seattle Genetics (now Seagen) and Pfizer (NYSE: PFE), which is in the process of buying Seagen.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze